Onco-Hematología

  • Gammapatías monoclonales
  • Síndromes linforoliferativos
  • Leucemias agudas mieloblásticas
  • Hemostasia y cáncer

ARANTZA ONAINDIA PÉREZ

Anatomía Patológica

CARLOS DE MIGUEL SÁNCHEZ

Hematología

XABIER GUTIÉRREZ LÓPEZ DE OCÁRIZ

Hematología

AINHOA VITERI JUSUE

Radiología

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.
Mosquera Orgueira, A., Perez Encinas, M.M., Diaz Varela, N.A., Mora, E., Díaz-Beyá, M., Montoro, M.J., Pomares, H., Ramos, F., Tormo, M., Jerez, A., Nomdedeu, J.F., De Miguel Sanchez, C., Leonor, A., Cárcel, P., Cedena Romero, M.T., Xicoy, B., Rivero, E., Del Orbe Barreto, R.A., Diez-Campelo, M., Benlloch, L.E., Crucitti, D., Valcárcel, D..

Hemasphere, 7, 961. 2023
Urgent and unexpected findings in oncology and hematology patients: a practical approach to imaging..
Viteri Jusue, A, Dominguez Fernandez, S, Perez Persona, E, Poza de Celis, R.

Radiologia, 64, 464-472. 2022
Velcadito: Low dose of bortezomib with melphalan and prednisone for >= 75-year-olds newly diagnosed with multiple myeloma.
Perez-Persona, E, Oiartzabal-Ormategui, I, Herraez, S, Menchaca, C, Cuevas-Palomares, L, Santamaria-Lopez, A, Diez-Angulo, R, Robles-Castro, D, de Miguel-Sanchez, C, Gabilondo-Jalon, M, Pison-Herrero, C, Unamunzaga-Cilaurren, A, Gonzalez-Vinaspre, AV, Salcedo-Cuesta, L, Mendizabal-Abad, A, de Castro, JMG.

EUROPEAN JOURNAL OF HAEMATOLOGY, 108, 532-535. 2022
Treatment burden in multiple myeloma according to comorbidity in real life.
Persona, EP, Ormategui, IO, Palomares, LC, Lopez, AS, de Castro, DR, de Sanchez, CM, Jalon, MG, Herrero, CP, Cilaurren, AU, de Vinaspre, AVG, de Castro, JMG.

ANNALS OF HEMATOLOGY, 101, 437-440. 2022
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies..
Tamariz-Amador LE, Battaglia AM, Maia C, Zherniakova A, Guerrero C, Zabaleta A, Burgos L, Botta C, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Martín-Sánchez E, Paiva B, The Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) Cooperative.

BLOOD CANCER JOURNAL, 11, 202-202. 2021
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, P, Loscertales, J, Terol, MJ, Payer, AR, Ortiz, M, Perez, I, Cuellar-Garcia, C, de la Mata, MF, Rodriguez, A, Lario, A, Delgado, J, Godoy, A, Perez, JMA, Berruezo, MJ, Oliveira, A, Hernandez-Rivas, JA, Malo, MDG, Medina, A, Martin, PG, Osorio, S, Baltasar, P, Fernandez-Zarzoso, M, Marco, F, Mancenido, MJV, Simonovich, AS, Rubio, ML, Jarque, I, Suarez, A, Alvarez, RF, Anchel, AL, Rios, E, Castillo, MDL, Persona, EP, Munoz, RG, Ramos, R, Yanez, L, Bello, JL, Loriente, C, Acha, D, Villanueva, M.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, 985-999. 2021
WHAT IS BEHIND HEMOPHAGOCYTIC SYNDROME? EXPERIENCE OF A CENTER.
Roldan, GV, Arzuaga, MJ, Aranguren, DCL, Martin, MX, De Pedro, OJ, Garcia, OS, Guerra, GE, Elicegui, FL, Oiartzabal, OI, Modesto, CM, Cerrato, CC, Robles, DCD, De Miguel, SC, Hernandez, HJ, Amutio, DE, Astigarraga, AI, Garcia-Ruiz, JC.

Haematologica, 106, 286-287. 2021
DOI:
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group..
Palanques-Pastor, Tomas, Megias-Vericat, Juan Eduardo, Martinez, Pilar, Lopez Lorenzo, Jose Luis, Cornago Navascues, Javier, Rodriguez Macias, Gabriela, Cano, Isabel, Arnan Sangerman, Montserrat, Vidriales Vicente, Maria Belen, Algarra Algarra, Jesus Lorenzo, Foncillas, Maria Angeles, Herrera, Pilar, Botella Prieto, Carmen, Vives, Susana, Figuera Alvarez, Angela, Cuevas Palomares, Laida, Sobas, Marta, Contento Gonzalo, Alejandro, Cuello Garcia, Rebeca, Amutio Diez, Maria Elena, De Miguel Llorente, Dunia, Navas Elorza, Begona, Bergua Burgues, Juan Miguel, Bernal Del Castillo, Teresa, Mateos Rodriguez, Maria Carmen, de Cabo Lopez, Erik, Franco Villegas, Ana Carolina, Garcia Boyero, Raimundo, Escolano Escobar, Cristian, Seri Merino, Cristina, Cervero, Carlos, Roldan Perez, Alicia, Hermosin Ramos, Lourdes, Cervera Calvo, Marta, Olave, Maria Telesa, Villafuerte Gutierrez, Paola, de Laiglesiai, Almudena, Serrano, Josefina, Najera Irazu, Maria Josefa, Pinana, Jose Luis, Sanz, Miguel Angel, Martinez-Lopez, Joaquin, Montesinos, Pau.

LEUKEMIA & LYMPHOMA, 62, 1-11. 2021
Molecular Update and Evolving Classification of Large B-Cell Lymphoma..
Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C.

Cancers, 13, 3352. 2021
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo, MJ, Bustamante, G, Gonzalez, E, Vazquez-Alvarez, J, Garcia, R, Ramirez-Payer, A, Perez-Persona, E, Abella, E, Garzon, S, Garcia, A, Jarque, I, Gonzalez, MS, Sampol, A, Motllo, C, Marti, JM, Alcala, M, Duro, R, Gonzalez, Y, Sastre, JL, Sarra, J, Lostaunau, G, Lopez, R, de la Rubia, J.

ANNALS OF HEMATOLOGY, 100, 1769-1778. 2021
Diffuse bone marrow metastases of small cell carcinoma with associated erythrophagocytosis mimicking acute leukaemia..
De Miguel Sanchez, Carlos, Robles de Castro, Diego, Cordoba Alonso, Ana Isabel, Guinea de Castro, Jose Maria.

Hematology, transfusion and cell therapy, 44, 459-461. 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience..
Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, 413-420. 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial..
Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV.

BLOOD CANCER JOURNAL, 11, 101-101. 2021
Primary plasma cell leukaemia presenting with flower-shaped nuclei.
Sanchez, CD, de Castro, DR, Herrero, CP, Persona, EP, Cuesta, LS, de Castro, JMG.

BRITISH JOURNAL OF HAEMATOLOGY, 193, 689-689. 2021
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
Gonzalez-Rincon, J, Garcia-Vela, JA, Gomez, S, Fernandez-Cuevas, B, Nova-Gurumeta, S, Perez-Sanz, N, Alcoceba, M, Gonzalez, M, Anguita, E, Lopez-Jimenez, J, Gonzalez-Barca, E, Yanez, L, Perez-Persona, E, de la Serna, J, Fernaadez-Zarzoso, M, Deben, G, Penalver, FJ, Fernandez, MC, de Oteyza, JP, Andreu, MA, Ruiz-Guinaldo, MA, Paz-Arias, R, Garcia-Malo, MD, Recasens, V, Collado, R, Cordoba, R, Navarro-Matilla, B, Sanchez-Beato, M, Garcia-Marco, JA.

PLOS ONE, 16, . 2021
Faggot cells in therapy-related acute myeloid leukemia with inv(16).
de Vinaspre, AVG, Sanchez, CD, De Castro, DR, Galiacho, VR, Abad, AM, De Castro, JMG.

Clinical case reports, 9, 572-573. 2021
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
Garcia-Munoz, R, Quero, C, Perez-Persona, E, Domingo-Garcia, A, Perez-Lopez, C, Villaescusa-de-la-Rosa, T, Martinez-Castro, AM, Arguinano-Perez, JM, Parra-Cuadrado, JF, Panizo, C.

BRITISH JOURNAL OF HAEMATOLOGY, 188, 661-673. 2020
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance..
García-Marco JA, López Jiménez J, Recasens V, Fernández Zarzoso M, González-Barca E, Somolinos De Marcos N, Ramírez MJ, Peñalver Parraga FJ, Yañez L, De La Serna Torroba J, Garcia Malo MD, Deben Ariznavarreta G, Perez Persona E, Ruiz Guinaldo MA, De Paz Arias R, Bañas Llanos E, Jarque I, Fernandez Valle MDC, Carral Tatay A, Perez De Oteyza J, Donato Martin E, Perez Fernández I, Martinez Martinez R, Andreu Costa MA, Champ D, García Suarez J, González Diaz M, Ferrer S, Carbonell F, García-Vela JA.

Haematologica, 104, 2249-2257. 2019